10 results · 19ms · Sources: EU EUDAMED, US FDA

Get notified when this changes

We'll email you when new records match this search — new devices, new clearances, certificate changes, or withdrawals.

PGLA90 Poly(glycolide-co-L-lactide) Surgical Sutures (Calypso); PGLA90 Poly(glycolide-co-L-lactide) Surgical Sutures (Odysseus)

FDA 510(k)
FDA Class 2 ·General, Plastic Surgery

Q-FIX

FDA UDI
Smith & Nephew, Inc.·00885556724729·REUSABLE BONE PUNCH 2.8MM Q-FIX IMPLANT

PARAPOST PARACORE AUTOMIX 5ML

FDA 510(k)
FDA Class 2 ·Dental

Ponto Bone Anchored Hearing System

FDA 510(k)
FDA Class 2 ·Ear, Nose, Throat

DEXCOM G6 CONTINUOUS GLUCOSE MONITORING SYSTEM

FDA Adverse Event
Malfunction ·DEXCOM, INC.·Product code QBJ·September 10, 2025

PUMP MMT-512LNAS PRDGM INS SK EN US LN

FDA Adverse Event
Injury ·MEDTRONIC MINIMED·Product code LZG·December 4, 2008

SCORPIO PS FEMUR WAFFLE POSTS W/LFIT

FDA Adverse Event
Injury ·STRYKER ORTHOPAEDICS MAHWAH·Product code JWH·September 13, 2011

GYNECARE X-TRACT MOTOR DRIVE UNIT

FDA Adverse Event
Malfunction ·ETHICON INC.·Product code HET·July 29, 2013

BIOMET StageOne Knee Tibial Cement Spacer Mold, 75 MM, Silicone, Sterile, Item 433175.

FDA Enforcement
Class II ·Terminated·Biomet, Inc.·April 15, 2020

Boston Scientific TELIGEN, Implantable Cardiac Defibrillator models E102, E110, the following models are not available in the US: models E103, E111, F102, F103, F110, F111. Sterilized using ethylene oxide. Product Usage: This family of implantable cardioverter defibrillators (ICDs) provide a variety of therapies including: -Ventricular tachyarrhythmia therapy, which is used to treat rhythms associated with sudden cardiac death such as VT and VF; -Bradycardia pacing, including adaptive rate pacing, to detect and treat bradyarrhythmias and to provide cardiac rate support after defibrillation therapy. Boston Scientific implantable cardioverter defibrillators (ICDs) are indicated to provide ventricular antitachycardia pacing (ATP) and ventricular defibrillation for automated treatment of life-threatening ventricular arrhythmias

FDA Enforcement
Class II ·Terminated·Boston Scientific CRM Corp·October 29, 2014